![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Lehr Matthias
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.11, Iss.7, 2001-07, pp. : 1123-1136
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Phospholipase A2 inhibitors in development
Expert Opinion on Investigational Drugs, Vol. 6, Iss. 3, 1997-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Amandi-Burgermeister E. Tibes U. Kaiser B.M. Friebe W.G. Scheuer W.V.
European Journal of Pharmacology, Vol. 326, Iss. 2, 1997-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Phospholipase A2 inhibitors promising in CHD
Inpharma, Vol. 1, Iss. 1633, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The therapeutic potential for phospholipase A2 inhibitors
Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. :